Mira Pharmaceuticals Inc (MIRA)

$1.00 0.00 (N/A)
Market Cap 42.02M
Revenue (ttm) 0.00
Net Income (ttm) -10.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 73,700
Avg Vol 144,542
Day's Range N/A - N/A
Shares Out 42.02M
Stochastic %K 9%
Beta 1.43
Analysts Sell
Price Target $11.00

Company Profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 786 432 9792
Address:
1200 Brickell Avenue, Suite 1950 #1183, Miami, United States
Jaespresso
Jaespresso Jun. 8 at 12:48 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Jun. 5 at 9:14 PM
$MIRA
1 · Reply
KPW963
KPW963 Jun. 5 at 8:00 PM
$MIRA the market is bleeding today ! I have absolutely no stress about $MIRA tho ! We got some huge news last weeks !
0 · Reply
johnnys_enchiladas
johnnys_enchiladas Jun. 4 at 4:16 PM
$MIRA Exciting times
1 · Reply
Jaespresso
Jaespresso Jun. 4 at 2:13 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Jun. 4 at 2:05 PM
$MIRA "With this agreement, MIRA now controls global development and commercialization rights across its entire pipeline - Ketamir-2, MIRA-55, and SKNY-1. As we advance Ketamir-2 into Phase 2a and move both MIRA-55 and SKNY-1 toward IND filings, having a clean, unified worldwide rights structure in place is exactly where we need to be. It strengthens our position with partners, with investors, and across every market we intend to operate in."
1 · Reply
RaphaelRapoport
RaphaelRapoport Jun. 4 at 12:24 PM
So now Miralogx has license rights to all $MIRA and $TELO assets ???
1 · Reply
DARKP00L
DARKP00L Jun. 4 at 12:03 PM
$MIRA 08:02 on Jun. 04 2026 MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1 #tradeideas
0 · Reply
Jaespresso
Jaespresso Jun. 3 at 8:36 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Jun. 2 at 2:18 PM
$MIRA
0 · Reply
Latest News on MIRA
Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

2026-06-04T12:27:50.000Z - 4 days ago

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

Jun 4, 2026, 8:00 AM EDT - 4 days ago

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

Mira Pharmaceuticals secures worldwide rights for Ketamir-2

2026-05-27T14:14:46.000Z - 12 days ago

Mira Pharmaceuticals secures worldwide rights for Ketamir-2

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

May 27, 2026, 8:00 AM EDT - 12 days ago

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

Mira Pharmaceuticals management to meet with Maxim

2026-05-26T16:54:44.000Z - 13 days ago

Mira Pharmaceuticals management to meet with Maxim

Mira announces results from Phase 1 trial evaluating Ketamir-2

2026-05-14T16:26:48.000Z - 25 days ago

Mira announces results from Phase 1 trial evaluating Ketamir-2

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

May 14, 2026, 8:00 AM EDT - 25 days ago

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

Mira announces acceptance of peer-reviewed SKNY-1 manuscript

2026-05-13T16:28:17.000Z - 26 days ago

Mira announces acceptance of peer-reviewed SKNY-1 manuscript

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

May 13, 2026, 8:00 AM EDT - 26 days ago

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Mira reports Mira-55 shows no THC-, Rimonabant-associated CNS side effects

2026-03-23T13:20:25.000Z - 2 months ago

Mira reports Mira-55 shows no THC-, Rimonabant-associated CNS side effects

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Mar 23, 2026, 9:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Mira Pharmaceuticals completes Phase 1 dosing of Ketamir-2

2026-03-04T13:43:05.000Z - 3 months ago

Mira Pharmaceuticals completes Phase 1 dosing of Ketamir-2

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Mar 4, 2026, 8:00 AM EST - 3 months ago

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study

2026-02-03T12:45:38.000Z - 4 months ago

Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

Feb 3, 2026, 7:30 AM EST - 4 months ago

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

Mira Pharmaceuticals initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:40.000Z - 5 months ago

Mira Pharmaceuticals initiated with a Buy at Rodman & Renshaw

Mira Pharmaceuticals initiates MAD Phase 1 study of oral ketamir-2

2025-10-24T11:36:06.000Z - 8 months ago

Mira Pharmaceuticals initiates MAD Phase 1 study of oral ketamir-2

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Oct 24, 2025, 7:30 AM EDT - 8 months ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Mira Pharmaceuticals announces preclinical data on oral Mira-55

2025-10-16T11:40:17.000Z - 8 months ago

Mira Pharmaceuticals announces preclinical data on oral Mira-55

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Oct 16, 2025, 7:30 AM EDT - 8 months ago

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Mira Pharmaceuticals closes acquisition of SKNY Pharmaceuticals

2025-09-30T11:45:26.000Z - 8 months ago

Mira Pharmaceuticals closes acquisition of SKNY Pharmaceuticals

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 30, 2025, 7:30 AM EDT - 8 months ago

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Mira Pharmaceuticals announces topline results from Phase 1 SAD study

2025-09-22T12:50:08.000Z - 9 months ago

Mira Pharmaceuticals announces topline results from Phase 1 SAD study

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 22, 2025, 8:00 AM EDT - 9 months ago

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Mira Pharmaceuticals reports Ketamir-2 data in PTSD

2025-09-16T11:35:06.000Z - 9 months ago

Mira Pharmaceuticals reports Ketamir-2 data in PTSD

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 16, 2025, 7:30 AM EDT - 9 months ago

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Mira Pharmaceuticals shareholders approve acquisition of SKNY Pharmaceuticals

2025-09-12T11:35:27.000Z - 9 months ago

Mira Pharmaceuticals shareholders approve acquisition of SKNY Pharmaceuticals

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Sep 12, 2025, 7:30 AM EDT - 9 months ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 19, 2025, 8:30 AM EDT - 10 months ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

Aug 12, 2025, 8:30 AM EDT - 10 months ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 30, 2025, 7:30 AM EDT - 11 months ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 29, 2025, 7:30 AM EDT - 11 months ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 11, 2025, 8:00 AM EDT - 11 months ago

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jul 3, 2025, 8:00 AM EDT - 1 year ago

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Jun 30, 2025, 8:00 AM EDT - 1 year ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 25, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

Jun 18, 2025, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 8, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

May 6, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 23, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 16, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 24, 2025, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 13, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Mar 4, 2025, 8:00 AM EST - 1 year ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 19, 2024, 9:00 AM EST - 1 year ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Dec 10, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Nov 20, 2024, 7:44 AM EST - 1 year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 28, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Oct 21, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 27, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 18, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Sep 11, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 26, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 19, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Aug 12, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Jul 25, 2024, 7:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jul 22, 2024, 8:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Jul 15, 2024, 7:00 AM EDT - 2 years ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Jun 24, 2024, 8:30 AM EDT - 2 years ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

May 29, 2024, 8:45 AM EDT - 2 years ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

May 21, 2024, 8:45 AM EDT - 2 years ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

May 20, 2024, 8:00 AM EDT - 2 years ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Jaespresso
Jaespresso Jun. 8 at 12:48 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Jun. 5 at 9:14 PM
$MIRA
1 · Reply
KPW963
KPW963 Jun. 5 at 8:00 PM
$MIRA the market is bleeding today ! I have absolutely no stress about $MIRA tho ! We got some huge news last weeks !
0 · Reply
johnnys_enchiladas
johnnys_enchiladas Jun. 4 at 4:16 PM
$MIRA Exciting times
1 · Reply
Jaespresso
Jaespresso Jun. 4 at 2:13 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Jun. 4 at 2:05 PM
$MIRA "With this agreement, MIRA now controls global development and commercialization rights across its entire pipeline - Ketamir-2, MIRA-55, and SKNY-1. As we advance Ketamir-2 into Phase 2a and move both MIRA-55 and SKNY-1 toward IND filings, having a clean, unified worldwide rights structure in place is exactly where we need to be. It strengthens our position with partners, with investors, and across every market we intend to operate in."
1 · Reply
RaphaelRapoport
RaphaelRapoport Jun. 4 at 12:24 PM
So now Miralogx has license rights to all $MIRA and $TELO assets ???
1 · Reply
DARKP00L
DARKP00L Jun. 4 at 12:03 PM
$MIRA 08:02 on Jun. 04 2026 MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1 #tradeideas
0 · Reply
Jaespresso
Jaespresso Jun. 3 at 8:36 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Jun. 2 at 2:18 PM
$MIRA
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 1 at 7:48 PM
$MIRA
0 · Reply
trekker314
trekker314 May. 29 at 5:54 PM
$MIRA My fellow MIRA investors, sorry to say i would be happy if stays at this level for a little while. When $SLS gets bought by BP i plan to use those gains to buy at least 100,000 shares of Mira and hold for 3 years until Ketamir-2 gets approved. Bullish on both stocks.
1 · Reply
lisaparsons
lisaparsons May. 28 at 2:33 PM
$MIRA what are everyones thoughts here? down 45% and wondering do i just leave it. i could use a tax loss from other investments and get in after but it could run . I am just shocked it hasnt really run after getting or applying for world rights. having suffered depression 99 percent of my life i believe in product but unsure why no institituions are interested. help. lol, have a blessed day.
2 · Reply
StockScanners
StockScanners May. 28 at 4:00 AM
$MIRA keeping an eye on 1.10 support here. If this zone continues holding, could see a bounce setup start developing from these levels.
0 · Reply
KPW963
KPW963 May. 27 at 7:33 PM
$MIRA @Moobumples what do you think about the news
0 · Reply
LUMMiii
LUMMiii May. 27 at 6:59 PM
$ASTC $NTCL $AIM GOOD news at $MIRA should be running right now
0 · Reply
prismmarketview
prismmarketview May. 27 at 4:43 PM
PRISM Mid-Day Movers: Aerospace & Defense and Comms & Media are Today’s Leaders. Astrotech Corp (NASDAQ: $ASTC ) is exploding higher, up about 500% to $15 after touching a new 52‑week high near $19.75 on massive volume versus normal trading. Digital Turbine (NASDAQ: $APPS) is ripping, up about 56% to $7.48, trading near its 52‑week high on massive volume after a strong Q4. Other notable Movers: Momentus Inc. ($MNTS ) up 22% Mira Pharmaceuticals ($MIRA) up 18% Mullen Automotive ($MULN.X)down -19% #MidDayMovers #Stockmarket #trading https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-comms-media-are-todays-leaders/
0 · Reply
Jaespresso
Jaespresso May. 27 at 4:22 PM
$MIRA
0 · Reply
rnrsly
rnrsly May. 27 at 3:22 PM
$MIRA https://finance.yahoo.com/sectors/healthcare/articles/mira-pharmaceuticals-secures-worldwide-rights-120000886.html
0 · Reply
rnrsly
rnrsly May. 27 at 2:56 PM
$MIRA Great news. Finally picking up some steam. Needs more volume to blast off!
0 · Reply
Vcass1
Vcass1 May. 27 at 2:53 PM
$MIRA expanded IP coverage for Ketamir-2. LFG big win for MIRA
0 · Reply
KPW963
KPW963 May. 27 at 12:54 PM
$MIRA
0 · Reply